新诊断鼻咽癌调强放疗后放射性鼻咽坏死(INN)的临床特征及治疗策略的影响
回顾2008至2019年经病理诊断的初诊鼻咽癌调强放疗后鼻咽坏死患者,按倾向评分匹配无坏死患者,评估治疗策略对坏死发生的影响。鼻咽坏死发生率为1.9%,共纳入53例坏死患者,头痛和恶臭为主要症状,71.7%在放疗期间或结束时存在假膜。化疗或分子靶向治疗与放疗联合与鼻咽坏死发生无关,而推量剂量(OR 7.360;95%CI 2.301-23.547;p=0.001)是其预测因素。
要点
- 初诊鼻咽癌调强放疗后鼻咽坏死发生率为1.9%,共纳入53例坏死患者。
- 头痛和恶臭为主要症状,71.7%的病例在放疗期间或结束时出现假膜。
- 推量剂量是鼻咽坏死的预测因素(OR 7.360;95%CI 2.301-23.547;p=0.001),化疗或分子靶向治疗与放疗联合与坏死发生无关。
核心结论
- 在调强放疗时代,初诊鼻咽癌患者的鼻咽坏死严重程度有所减轻。
- 本研究表明治疗策略对鼻咽坏死的发生贡献较小,而放疗累积剂量可能与其发生相关。
研究设计与样本
- 回顾性分析2008至2019年经病理诊断为初诊鼻咽癌调强放疗后鼻咽坏死的患者,并按倾向评分与本中心无鼻咽坏死患者进行匹配。
- 采用单因素和多因素logistic回归分析评估治疗策略对鼻咽坏死发生的影响。
主要发现
- 初诊鼻咽癌人群中鼻咽坏死发生率为1.9%,共纳入53例鼻咽坏死患者。
- 头痛和恶臭为主要症状,71.7%的病例在放疗期间或结束时存在假膜。
- 所有患者均处于早期或中期鼻咽坏死,无患者出现颅底放射性骨坏死。
- 基于倾向评分匹配纳入212例无鼻咽坏死患者,鼻咽坏死组与非鼻咽坏死组的总生存曲线相似(p=0.248),无进展生存曲线也相似(p=0.266)。
- 推量剂量是鼻咽坏死的预测因素(OR 7.360;95%CI 2.301-23.547;p=0.001),但未能确定预测鼻咽坏死发生的最佳累积剂量阈值。
关键数值与推荐
- 化疗或分子靶向治疗与放疗联合与鼻咽坏死发生无关。
- 推量剂量是鼻咽坏死的预测因素(OR 7.360;95%CI 2.301-23.547;p=0.001)。
- 未能确定预测鼻咽坏死发生的最佳累积剂量阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To define the clinical characteristics of irradiation-induced nasopharyngeal necrosis (INN) after intensity-modulated radiotherapy (IMRT) and identify the influence of treatment strategies on INN in primary nasopharyngeal carcinoma (NPC) patients. PATIENTS AND METHODS: From 2008 to 2019, NPC patients pathologically diagnosed with INN after primary IMRT were reviewed. Those patients were matched with propensity scores for patients without INN in our center. The impact of treatment strategies on INN occurrence was assessed using univariate and multivariate logistic regression analysis. RESULTS: The incidence rate of INN was 1.9% among the primary NPC population, and 53 patients with INN were enrolled. Headache and foul odor were the main symptoms, and 71.7% of cases had pseudomembrane during or at the end of radiotherapy. All patients were in early or middle stage INN, and no one presented with skull-based osteoradionecrosis. Then 212 non-INN patients were included based on propensity scores match. Overall survival (p = 0.248) and progression-free survival (p = 0.266) curves were similar between the INN and non-INN groups. Treatment strategies including combining chemotherapy or molecular targeted therapy with radiotherapy were not associated with INN occurrence, while boost dose (OR 7.360; 95% CI 2.301-23.547; p = 0.001) was a predictor factor for it. However, the optimal threshold for an accumulated dose to predict INN's occurrence was failed to determine. CONCLUSION: In the IMRT era, the severity of INN in primary NPC patients is lessened. This study showed that treatment strategies contributed little to develop INN, while the accumulated dose of radiation may relate to its occurrence.
引用
- Xu Y, Liu Y, Wang Z, et al. Irradiation-induced nasopharyngeal necrosis (INN) in newly diagnosed nasopharyngeal carcinoma treated by intensity-modulated radiation therapy: clinical characteristics and the influence of treatment strategies. Radiat Oncol. 2022. PMID: 35062991. doi:10.1186/s13014-022-01980-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。